Every 8-K that Rani Therapeutics Holdings, Inc. (RANI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow RANI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RANI filings page.
Rani Therapeutics Holdings, Inc. reported second quarter 2026 results and a corporate update. The company highlighted positive initial Phase 1a data for RT-114, an orally administered RaniPill Capsule delivering PG-102, showing oral bioavailability greater than 150% relative to matched subcutaneous dosing, with no serious adverse events and no events attributed to the RaniPill Capsule.
Rani completed a $20 million registered direct offering led by a sovereign wealth fund, entered a new obesity and metabolic disease collaboration with PegBio, and appointed Nicholas Maestas as Chief Financial Officer and Michelle Gilson to the Board. Cash, cash equivalents and marketable securities totaled $53.4 million as of June 30, 2026, and the company expects this to fund operations at least through 2027. For the quarter, contract revenue was $1.7 million versus none a year earlier, research and development expenses were $5.0 million, general and administrative expenses were $5.5 million, and net loss was $8.4 million compared with $11.2 million in 2025.
Rani Therapeutics Holdings, Inc. appointed Michelle Gilson to its Board of Directors on August 1, 2026, and named her chair of the Audit Committee, with her term running until the earlier of the next annual meeting of stockholders, the qualification of a successor, or her death, resignation, or removal.
Gilson, age 34, is the former Chief Financial Officer of Arcellx, Inc., serving from May 2022 through its acquisition by Gilead Sciences, Inc. in April 2026, and previously held biotechnology equity research and investment banking roles at several financial firms. She will serve as a non-employee director and receive compensation under the company’s Non-Employee Director Compensation Policy and will enter into the company’s standard indemnification agreement. The company states there are no arrangements or understandings regarding her appointment, no family relationships with other directors or executive officers, and no transactions requiring disclosure under Item 404(a) of Regulation S-K.
Rani Therapeutics Holdings, Inc. appointed Nicholas M. Maestas as Chief Financial Officer, principal financial officer, and principal accounting officer effective June 29, 2026, succeeding Svai Sanford. Maestas brings prior CFO and strategy experience from Tempest Therapeutics and finance roles at other biotechnology companies.
Under his June 24, 2026 offer letter, Maestas will receive a $500,000 annual base salary and be eligible for an annual bonus targeted at 75% of base salary. He will be granted a non-qualified option to purchase 2,000,000 shares of Class A common stock under Rani’s 2026 Equity Inducement Plan, vesting over four years, with 25% vesting after one year and the balance monthly over 36 months of continuous service.
The Board approved the new 2026 Equity Inducement Plan on June 28, 2026, reserving 5,500,000 shares of Class A common stock for inducement awards to new hires under Nasdaq Rule 5635(c)(4), which does not require stockholder approval. The plan’s terms are described as substantially similar to the company’s stockholder-approved 2021 Equity Incentive Plan.
Rani Therapeutics Holdings, Inc. held its annual stockholder meeting on May 28, 2026. Stockholders voted together as a single class, with one vote per share of both Class A and Class B common stock. As of April 2, 2026, there were 99,812,515 Class A shares and 23,970,359 Class B shares outstanding and entitled to vote.
All seven director nominees, including Talat Imran, Mir Imran, and the other board members listed, were elected to serve until the 2027 annual meeting or until successors are elected and qualified. Stockholders also ratified the appointment of CBIZ CPAs P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Rani Therapeutics Holdings, Inc. entered into a securities purchase agreement with institutional investors to conduct a registered offering of equity. The deal covers 12,476,637 shares of Class A common stock at $1.07 per share and pre-funded warrants to purchase 6,214,953 shares at an exercise price of $0.0001 per share, sold at $1.0699 per warrant.
The transaction is expected to generate approximately $20.0 million in gross proceeds before fees, with a 6.0% cash fee payable to the placement agents. Closing is expected on or about May 27, 2026, subject to customary conditions.
Rani agreed to a 90-day restriction on most new equity issuances and a nine-month restriction on new variable rate transactions, while directors, officers and certain stockholders signed 60-day lock-up agreements limiting sales of Rani securities.
Rani Therapeutics Holdings, Inc. reported first quarter 2026 results, received a Nasdaq minimum bid-price deficiency notice, and announced a planned Chief Financial Officer transition. Contract revenue rose to $1.7 million from $0.2 million, while research and development and general and administrative expenses declined year over year.
The company recorded a net loss of $8.0 million versus $12.7 million a year earlier and ended March 31, 2026 with $43.4 million in cash, cash equivalents and marketable securities, which it expects to fund operations into the fourth quarter of 2027. Nasdaq notified Rani that its shares failed to meet the $1.00 Minimum Bid Price Requirement for 30 consecutive business days, triggering a 180‑day cure period to November 9, 2026, with potential additional time if it moves to The Nasdaq Capital Market and, if needed, effects a reverse stock split. CFO Svai Sanford will resign following appointment of a successor and will receive nine months of base salary, COBRA premiums, and accelerated vesting of unvested equity under a separation agreement.
Rani Therapeutics reported fourth-quarter and full-year 2025 results while highlighting major strategic milestones. The company signed a collaboration and license agreement with Chugai worth up to $1.085 billion for oral delivery of a rare disease antibody using its RaniPill® platform and completed an oversubscribed private placement raising $60.3 million, including $6.0 million of debt conversion.
Cash, cash equivalents and marketable securities were $49.7 million as of December 31, 2025, up from $27.6 million a year earlier, and the company expects this, plus an anticipated Chugai milestone, to fund operations into the fourth quarter of 2027. Rani repaid all remaining Avenue debt in December 2025 and reported having no outstanding debt at year-end.
For 2025, contract revenue was $1.6 million, research and development expenses fell to $20.2 million and general and administrative expenses declined to $19.7 million, reflecting cost-containment efforts. Net loss narrowed to $41.0 million from $56.6 million in 2024, while the company advanced its pipeline with preclinical data for oral semaglutide and RT‑114 and initiation of a Phase 1 obesity study.
Rani Therapeutics Holdings, Inc. furnished an 8‑K announcing a corporate update and financial results for the three and nine months ended September 30, 2025. The company issued a press release on November 6, 2025, which is included as Exhibit 99.1 and incorporated by reference.
The information provided under Item 2.02, including Exhibit 99.1, is furnished and not deemed “filed” under Section 18 of the Exchange Act, and will only be incorporated into other filings if specifically referenced.
Rani Therapeutics Holdings, Inc. closed a private placement of 42,633,337 shares of Class A common stock, together with warrants to purchase up to 125,000,004 shares and pre-funded warrants to purchase up to 82,366,667 shares. Following the closing, shares outstanding were 97,541,221.
In connection with the financing, Andrew Farquharson and Maulik Nanavaty resigned from the board effective upon closing. The company appointed Abraham Bassan and Vasudev Bailey, Ph.D. to the board, naming Mr. Bassan chair of Nominating and Corporate Governance and Dr. Bailey chair of Compensation. For so long as Samsara BioCapital and Anomaly Ventures each beneficially own at least 25% of the securities issued to it at closing (including upon exercise of the warrants), each has the right to designate one board member, subject to Nasdaq rules.
Rani Therapeutics entered a private placement to raise approximately $60.3 million in gross proceeds. The Company agreed to sell 42,633,337 Class A shares, issue warrants to purchase up to 125,000,004 shares, and issue pre-funded warrants for up to 82,366,667 shares. Institutional investors will pay $0.48 per share; an affiliated investor will pay $0.605 per share. Pre-funded warrants are exercisable immediately at $0.0001 per share; common warrants become exercisable following stockholder approval and have a five-year term.
As part of the financing, Avenue agreed to convert $6.0 million of loans into 12,500,000 shares (or pre-funded warrants) and will receive warrants to purchase up to 12,500,000 shares on the same terms. Rani also signed a collaboration and license agreement with Chugai, adding $10.0 million upfront, up to $18.0 million in technology transfer milestones, up to $57.0 million in development milestones, up to $100.0 million in sales-based milestones, and single-digit royalties.
The Company will file resale registration statements within 15 days of closing and use reasonable best efforts to have them declared effective 45 days after closing, or 90 days if subject to full review.
Rani Therapeutics (Nasdaq:RANI) filed an 8-K disclosing receipt of a Nasdaq minimum-bid-price deficiency notice. The stock closed below $1.00 for 30 consecutive business days, violating Listing Rule 5450(a)(1).
The Company has 180 days, until December 17 2025, to lift its bid to at least $1.00 for 10 straight sessions. If unsuccessful, Rani may seek a second 180-day grace period by moving to the Nasdaq Capital Market and, if needed, enacting a reverse stock split. Failure to regain compliance would result in delisting.
Management is monitoring the share price and evaluating alternatives but gives no assurance of success. Liquidity, investor base and valuation could be materially affected if the listing is lost.